Related Experiment Video

Updated: Jul 15, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K

Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy

Huang Wen1, Zhu Yongling2, Zheng Shuying1

  • 1Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Department of Nephrology, Wenzhou, China.

Jornal Brasileiro De Nefrologia
|July 24, 2020
PubMed

Insights

Febuxostat effectively reduces uric acid and improves kidney function in patients with stage 3 diabetic nephropathy. This treatment is well-tolerated, though further long-term studies are needed.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy (DN) is a major complication of diabetes, often associated with elevated uric acid levels.
  • Chronic kidney disease (CKD) stage 3 patients with DN and hyperuricemia require effective management strategies.
  • Serum uric acid is increasingly recognized as a potential contributor to CKD progression.

Purpose of the Study:

  • To evaluate the efficacy and safety of febuxostat in improving renal function in patients with CKD stage 3 diabetic nephropathy.
  • To assess the impact of febuxostat on key markers of kidney function and damage.

Main Methods:

  • A randomized controlled trial involving CKD stage 3 DN patients with high serum uric acid.
  • Patients received standard care including diet, RAAS inhibitors, and hypoglycemic treatment; the treatment group additionally received febuxostat.
  • Renal function markers (serum creatinine, cystatin C, eGFR) and proteinuria were monitored over 24 weeks.

Main Results:

  • Febuxostat treatment led to significant improvements in serum uric acid, serum creatinine, cystatin C, and eGFR compared to the control group.
  • Significant reductions in proteinuria and albuminuria were observed in the febuxostat group.
  • Tubular markers also decreased, and 50% of patients achieved treatment goals within 4 weeks.

Conclusions:

  • Febuxostat demonstrates efficacy in reducing uric acid and improving renal function in CKD stage 3 diabetic nephropathy patients.
  • The drug is well-tolerated, suggesting a favorable safety profile.
  • The study's short duration necessitates further investigation to confirm long-term benefits and safety.
Abstract

More Related Videos

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

3.0K
Refined Murine Model of Idiopathic Pulmonary Fibrosis07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

746

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...